Pharmaceuticals

Global Connected Drug Delivery Devices Market Valuation and Growth Prospects: $60.28 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the connected drug delivery devices market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Connected Drug Delivery Devices Market Size?

The complement inhibitors market size has experienced significant growth in recent years. Its valuation is projected to increase from $16.41 billion in 2024 to $21.26 billion in 2025, at a compound annual growth rate (CAGR) of 29.6%. The expansion observed during the historic period can be attributed to several factors, including the rising prevalence of complement-mediated diseases, heightened awareness of rare conditions, the emergence of biologics as effective therapies, increasing healthcare expenditure, a growing focus on personalized medicine, the availability of orphan drug incentives, regulatory backing for rare disease treatments, and collaborations between pharmaceutical companies and research institutions.

The complement inhibitors market is poised for significant expansion in the coming years, with its size anticipated to reach $60.28 billion by 2029, exhibiting a robust compound annual growth rate (CAGR) of 29.8%. This expansion during the forecast period is primarily fueled by the increasing incidence of autoimmune and inflammatory diseases, the burgeoning biologics and biosimilar markets, a rise in clinical trials, the development of longer-acting complement inhibitors, the enhancement of healthcare infrastructure in emerging economies, greater adoption of targeted therapies, a growing geriatric population, and improved patient access to biologic treatments. Prominent trends expected in this period involve the integration of artificial intelligence in drug discovery, advanced techniques for biomarker identification, the application of machine learning for predicting patient responses, the creation of long-acting drug formulations, next-generation sequencing for analyzing the complement system, high-throughput screening platforms, the use of organ-on-a-chip models for complement inhibition testing, 3D bioprinting for complement inhibitor development, and real-time monitoring tools to assess treatment efficacy.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21155&type=smp

What Core Market Drivers Are Expanding The Connected Drug Delivery Devices Industry?

The intensifying focus on personalized medicine is projected to stimulate the growth of the complement inhibitors market moving forward. This approach involves customizing treatments for individual patients, based on their genetic, environmental, and lifestyle factors, to optimize outcomes and enhance care. The adoption of personalized medicine is expanding, driven by advancements in genomics, the increasing availability of biomarker-based diagnostics, improved data analytics technologies, and a rising demand for more targeted and effective therapies. Complement inhibitors operate akin to personalized medicine by precisely targeting specific components of the complement system, tailored to a patient’s unique disease profile, genetic makeup, and complement activity levels. For instance, in February 2024, the US-based nonprofit Personalized Medicine Coalition (PMC) indicated that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, representing a significant increase from the 12 approved in 2022. Thus, the escalating emphasis on personalized medicine is fueling the growth of the complement inhibitors market.

What Segment Insights Are Highlighted In The Connected Drug Delivery Devices Market Report?

The complement inhibitors market covered in this report is segmented –

1) By Product Type: Complement Component 3 (C3) Inhibitors, Complement Component 5 (C5) Inhibitors, Complement Factor D Inhibitors

2) By Mechanism Of Action: Alternative Pathway Inhibitors, Classic Pathway Inhibitors, Lectin Pathway Inhibitors

3) By Indication: Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Paroxysmal Nocturnal Hemoglobinuria (PNH)

4) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)

5) By Patient Demographics: Adult, Geriatric, Pediatric

Subsegments:

1) By Complement Component 3 (C3) Inhibitors: Small Molecule C3 Inhibitors, Monoclonal Antibody C3 Inhibitors, Peptide-Based C3 Inhibitors

2) By Complement Component 5 (C5) Inhibitors: Monoclonal Antibody C5 Inhibitors, Small Molecule C5 Inhibitors, RNA-Based C5 Inhibitors

3) By Complement Factor D Inhibitors: Small Molecule Factor D Inhibitors, Monoclonal Antibody Factor D Inhibitors

Which Notable Trends Are Transforming The Connected Drug Delivery Devices Market Outlook?

Leading companies in the complement inhibitors market are concentrating on developing monoclonal antibodies to effectively target and regulate the complement system in various autoimmune and inflammatory diseases. These lab-engineered proteins are designed to specifically target and bind to antigens, aiding in the treatment of conditions like cancer, autoimmune disorders, and infections. For example, in August 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, secured approval from the European Commission for PiaSky (crovalimab). This approval covers adults and adolescents with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to or have been previously treated with C5 inhibitors. PiaSky (crovalimab) is a monoclonal antibody that targets complement protein C5 to prevent its cleavage, thereby stopping the formation of the membrane attack complex (MAC). This mechanism inhibits terminal complement-mediated intravascular haemolysis. By reducing haemolysis, PiaSky assists in improving hemoglobin levels, decreasing the need for blood transfusions, and alleviating symptoms such as fatigue and anemia, thus enhancing patients’ quality of life.

Which Firms Are Driving Innovation Within The Connected Drug Delivery Devices Market?

Major companies operating in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/complement-inhibitors-global-market-report

What Regional Trends Are Shaping Growth In The Connected Drug Delivery Devices Market?

North America was the largest region in the complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complement inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21155&type=smp

Browse Through More Reports Similar to the Global Connected Drug Delivery Devices Market 2025, By The Business Research Company

Ace Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795